No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
111 |
4. Check minimum number of eventsNone |
111 |
5. Include endpointsNone |
111 |
6. Filter based on genotype QC (FinnGen only) |
94 |
Control definitions (FinnGen only)
- Control exclude
- F5_MENTRET
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- F70-F79
- Name in latin
- Retardatio mentalis gravis
Similar endpoints
↥List of similar endpoints to
Severe mental retardation
based on the number of shared cases.
Similar with more cases:
- Mental retardation, excluding more controls
- Mental retardation
- Mental retardation, wide definition
- Psychiatric diseases
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 5092 | 2194 | 2897 |
| Only index persons | 4034 | 1735 | 2299 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.06 | 0.08 |
| Only index persons | 0.08 | 0.06 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 23.02 | 24.33 | 22.03 |
| Only index persons | 22.29 | 23.33 | 21.50 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 94 | 36 | 58 |
| Unadjusted period prevalence (%) | 0.02 | 0.01 | 0.03 |
| Median age at first event (years) | 18.93 | 16.65 | 20.34 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 98
- Matched controls
- 980
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F72.0
ICD-10 Finland
Severe mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
76.3
63
*
N03AG01
ATC
valproic acid; systemic, rectal
26.9
54.8
45
30
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
21.1
49.5
47
41
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
44.1
39
*
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
12.9
35.2
46
63
N05BA01
ATC
diazepam; systemic, rectal
13.4
33.9
41
50
P85
ICPC
Mental retardation
+∞
33.2
30
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
12.1
28.9
36
45
N05BA09
ATC
clobazam; oral
54.2
28.4
33
9
F72.1
ICD-10 Finland
Severe mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
26.2
24
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
37.4
26.1
33
13
183
Kela drug reimbursment
Lamotrigin and topiramate
64.1
24.9
28
6
F79.9
ICD-10 Finland
Unspecified mental retardation, without mention of impairment of behaviour
+∞
22.8
21
*
N05CD08
ATC
midazolam; nasal, systemic
23.0
22.7
33
21
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
24.8
21.3
30
17
N03AX11
ATC
topiramate; oral
32.9
19.4
25
10
F71.0
ICD-10 Finland
Moderate mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
19.4
18
*
N03AX14
ATC
levetiracetam; systemic
19.1
18.8
29
21
F72.9
ICD-10 Finland
Severe mental retardation, without mention of impairment of behaviour
+∞
18.3
17
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
7.9
17.9
30
52
G40.4
ICD-10 Finland
Other generalized epilepsy and epileptic syndromes
77.5
17.4
19
*
L28
ICPC
Limited function/disability (L)
6.7
16.1
32
66
113
Kela drug reimbursment
Anxiety disorders associated with mental retardation
+∞
16.1
15
*
F70.0
ICD-10 Finland
Mild mental retardation, With the statement of no, or minimal, impairment of behaviour
+∞
15.0
14
*
N05AX08
ATC
risperidone; systemic
6.7
14.9
29
58
N03AG04
ATC
vigabatrin; oral
175.0
14.9
15
*
N03AX09
ATC
lamotrigine; oral
14.8
14.9
25
22
N03AF02
ATC
oxcarbazepine; oral
15.5
14.6
24
20
R56.8
ICD-10 Finland
Other and unspecified convulsions
7.0
14.4
26
48
A06AD11
ATC
lactulose; oral
6.5
14.1
28
57
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.7
14.1
27
53
N03AF01
ATC
carbamazepine; oral, rectal
22.4
14.1
20
11
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.0
13.9
48
159
G40.89
ICD-10 Finland
Other epilepsy
33.8
13.5
17
6
F73.0
ICD-10 Finland
Profound mental retardation, with the statement of no, or minimal, impairment of behaviour
+∞
12.8
12
*
M41.4
ICD-10 Finland
Neuromuscular scoliosis
+∞
12.8
12
*
181
Kela drug reimbursment
Retigabine and vigabatrin
148.2
12.8
13
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
4.9
12.6
38
112
RT274, ,
NOMESCO Finland
+∞
11.7
11
*
Z31.5
ICD-10 Finland
Genetic counselling
6.6
11.4
21
39
U04
ICPC
Incontinence urine
24.9
11.1
15
7
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
5.8
10.9
23
49
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.9
10.7
29
77
F79.1
ICD-10 Finland
Unspecified mental retardation, significant impairment of behaviour requiring attention or treatment
+∞
10.6
10
*
R5110, ,
SPAT
12.1
10.6
19
19
SPAT1262
SPAT
Handing over of treatment supplies
5.4
10.3
24
56
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
19.4
10.2
15
9
H50.30
ICD-10 Finland
Intermittent esotropy
24.6
9.6
13
6
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.4
9.4
21
47
SPAT1229
SPAT
Assessment of need for aid
11.2
9.2
17
18
JDB10
NOMESCO Finland
Percutaneous gastrostomy
27.0
9.2
12
5
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
13.4
8.9
15
13
R62.0
ICD-10 Finland
Delayed milestone
7.6
8.6
20
32
G41.9
ICD-10 Finland
Status epilepticus, unspecified
98.1
8.6
9
*
NAG53
NOMESCO Finland
Posterior or lateral fusion of thoracic spine with fixation, more than 3 vertebraea
98.1
8.6
9
*
N03AF03
ATC
rufinamide; oral
+∞
8.4
8
*
TJD20
NOMESCO Finland
Change of gastrostomy tube
36.7
8.2
10
*
N03AX18
ATC
lacosamide; systemic
20.4
7.8
11
6
R1260
NOMESCO Finland
Evaluation of communicative skills
20.4
7.8
11
6
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
4.3
7.7
23
65
3046, ,
Kela drug reimbursment
+∞
7.4
7
*
R1100
NOMESCO Finland
General evaluation of the need for rehabilitation
7.4
7.3
17
27
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
13.5
7.3
12
10
N03AX15
ATC
zonisamide; oral
32.7
7.3
9
*
G03DC03
ATC
lynestrenol; oral
32.7
7.3
9
*
R1240
NOMESCO Finland
Social assessment of need and possibilities of rehabilitation
32.7
7.3
9
*
F83
ICD-10 Finland
Mixed specific developmental disorders
8.6
7.2
15
20
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
18.3
6.9
10
6
R5140, ,
SPAT
43.2
6.9
8
*
RT490, ,
NOMESCO Finland
24.5
6.8
9
*
WYA20
NOMESCO Finland
Home visit
24.5
6.8
9
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.5
6.8
30
111
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.5
6.8
30
111
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
6.7
31
118
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
15.7
6.5
10
7
NA7EA
NOMESCO Finland
Scoliosis X-ray examination
15.7
6.5
10
7
WX408
NOMESCO Finland
General anesthesy, balanced
3.1
6.5
41
187
7803A
ICD-9 Finland
General symptoms, Convulsions
74.5
6.5
7
*
ADB00
NOMESCO Finland
Implantation of vagus nerve stimulating device
74.5
6.5
7
*
Z3229
NOMESCO Finland
Other healthcare associate professional
4.0
6.4
21
63
WYA30, ,
SPAT
19.6
6.4
9
5
G40.00
ICD-10 Finland
Benign childhood epilepsy with centrotemporal EEG spikes
28.7
6.3
8
*
N03AX22
ATC
perampanel; oral
28.7
6.3
8
*
WKEHK, ,
NOMESCO Finland
+∞
6.3
6
*
N03AA02
ATC
phenobarbital; systemic
+∞
6.3
6
*
1530, ,
Kela drug reimbursment
+∞
6.3
6
*
199
Kela drug reimbursment
Rufinamide
+∞
6.3
6
*
R5130, ,
SPAT
+∞
6.3
6
*
Q02
ICD-10 Finland
Microcephaly
+∞
6.3
6
*
N03AE01
ATC
clonazepam; systemic
9.6
6.3
12
14
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.1
6.3
35
149
R1250
NOMESCO Finland
Evaluation of functional capability
11.1
6.2
11
11
ZXE10
NOMESCO Finland
More than one and less than three hours
2.9
6.1
44
216
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
15
27
6.36
5.97
6.7
6.0
23.47
24.56
mmol/l
0.59
15
27
10
14
7.81
4.78
2.9
2.7
17.88
16.21
%
—
10
14
59
376
2.43
4.37
4.2
3.8
0.00
0.00
estimate
-0.00
13
51
63
414
2.46
4.35
12.0
13.7
1.22
1.22
mmol/l
0.01
58
385
58
370
2.39
4.25
4.2
3.8
0.00
0.00
estimate
-0.00
13
58
58
375
2.34
4.05
4.2
3.8
0.00
0.00
estimate
-0.00
13
56
24
104
2.73
3.99
8.8
19.0
106.25
104.33
mmol/l
1.00
24
104
25
114
2.60
3.75
2.0
2.1
—
—
—
0
0
14
46
3.38
3.70
3.9
2.8
—
—
—
0
0
34
181
2.35
3.67
4.9
3.8
0.00
0.00
estimate
-0.00
12
54
32
166
2.38
3.66
12.5
9.3
5.23
5.12
kpa
0.30
32
161
21
90
2.70
3.55
1.9
2.0
—
—
—
0
0
0
86
0.00
3.53
0.0
1.2
—
3.02
—
0
71
18
72
2.84
3.45
10.3
19.3
1.72
0.30
mmol/l
0.55
13
61
31
165
2.29
3.31
12.6
9.3
1.96
1.14
mmol/l
0.61
25
129
20
88
2.60
3.20
1.9
2.2
—
—
—
0
0
42
256
2.12
3.19
4.5
3.2
0.00
0.00
estimate
-0.00
12
48
16
63
2.84
3.14
9.1
16.9
123.13
124.06
g/l
0.05
16
63
0
79
0.00
3.12
0.0
2.4
—
—
—
0
0
45
285
2.07
3.07
3.3
4.6
—
—
—
0
0
53
357
2.06
3.05
5.1
8.2
19.85
20.40
umol/l
0.02
43
340
5
5
10.43
3.01
2.6
1.8
51.29
45.60
umol/l
—
5
5
17
71
2.69
3.00
11.1
19.5
5.28
5.05
kpa
0.69
17
71
17
71
2.69
3.00
11.1
19.4
12.13
14.04
kpa
0.69
17
71
0
69
0.00
2.73
0.0
1.7
—
3.53
—
0
49
0
70
0.00
2.72
0.0
2.2
—
—
—
0
0
10
30
3.59
2.69
1.8
1.9
—
—
—
0
0
16
310
0.42
2.61
1.3
2.1
—
—
—
0
0
30
179
1.97
2.31
3.7
2.4
0.00
0.00
estimate
-0.00
11
48
7
18
4.10
2.30
1.4
1.4
—
—
—
0
0
31
191
1.91
2.16
16.5
20.3
25.57
24.87
mmol/l
0.40
31
191
9
32
2.99
2.06
1.9
2.0
—
—
—
0
0
7
21
3.51
2.00
1.3
1.9
—
—
—
0
0
0
50
0.00
1.95
0.0
1.6
—
—
—
0
0
66
525
1.79
1.91
5.7
7.0
125.10
112.65
u/l
0.52
60
491
37
251
1.76
1.87
3.2
4.0
0.77
0.28
e6/l
0.45
27
184
7
23
3.20
1.83
4.3
2.5
554.86
268.78
ug/l
—
7
23
6
18
3.48
1.77
1.2
1.7
—
—
—
0
0
0
46
0.00
1.76
0.0
4.4
—
31.68
—
0
31
26
162
1.82
1.72
3.0
4.0
2.08
1.51
e6/l
0.16
13
87
7
25
2.93
1.68
1.9
1.7
—
—
—
0
0
10
43
2.47
1.64
1.7
1.3
—
—
—
0
0
6
135
0.41
1.55
1.7
2.2
—
—
—
0
0
5
15
3.45
1.54
1.8
1.7
—
—
—
0
0
9
37
2.57
1.52
2.0
7.9
23.39
23.86
mmol/l
—
9
37
5
121
0.38
1.50
1.8
2.1
—
—
—
0
0
9
39
2.44
1.47
19.1
30.3
25.11
23.82
mmol/l
—
9
39
27
179
1.70
1.44
4.7
3.5
1.02
1.02
kg/l
0.57
19
113
41
304
1.60
1.42
2.9
3.0
—
—
estimate
—
0
0
9
42
2.26
1.38
13.6
22.8
15.34
16.31
%
—
9
42
19
115
1.81
1.37
1.7
2.6
384.42
318.97
nmol/l
0.59
19
107
10
48
2.21
1.33
17.3
26.0
96.51
95.35
%
—
10
48
0
36
0.00
1.16
0.0
1.5
—
847.17
—
0
29
8
41
2.03
1.11
1.4
1.7
—
—
—
0
0
5
21
2.45
1.10
1.2
1.9
—
—
—
0
0
9
45
2.10
1.08
1.4
1.9
—
—
—
0
0
10
53
1.99
1.05
4.5
23.5
0.57
0.61
%
—
10
53
7
35
2.08
1.02
1.0
2.6
—
—
—
0
0
9
49
1.92
1.02
19.1
25.4
0.82
1.24
%
—
9
49
10
54
1.95
1.01
4.5
23.1
0.89
1.32
%
—
10
54
10
54
1.95
1.01
1.7
8.6
2.74
2.93
g/l
—
10
54
63
540
1.47
1.00
13.7
10.6
102.12
90.44
ml/min/173m2
1.88
53
449
0
30
0.00
0.99
0.0
1.3
—
0.04
—
0
6
14
87
1.71
0.93
1.6
1.8
606.44
435.68
pmol/l
—
9
80
31
237
1.45
0.88
4.4
3.0
2.35
2.39
mmol/l
1.34
31
221
49
568
0.73
0.80
3.2
3.8
1.21
1.19
mmol/l
0.10
43
540
0
25
0.00
0.80
0.0
1.4
—
5.75
—
0
17
52
596
0.73
0.78
3.7
4.2
1.33
1.42
mmol/l
0.88
45
567
9
53
1.77
0.78
6.8
8.0
—
—
—
0
0
5
95
0.50
0.70
1.2
1.1
—
—
—
0
0
61
676
0.74
0.68
3.9
3.7
—
—
—
0
0
8
50
1.65
0.63
21.1
25.0
0.65
0.66
%
—
8
50
84
786
1.48
0.63
19.5
14.0
39.62
23.96
mg/l
2.39
72
579
23
177
1.39
0.62
3.1
3.0
—
—
—
0
0
22
168
1.40
0.62
2.2
4.0
0.33
0.62
e6/l
—
9
92
0
20
0.00
0.61
0.0
1.5
—
—
—
0
0
0
21
0.00
0.61
0.0
1.4
—
1.23
—
0
12
0
21
0.00
0.61
0.0
3.1
—
6.18
—
0
21
0
21
0.00
0.61
0.0
1.4
—
0.96
—
0
12
0
21
0.00
0.61
0.0
1.4
—
1.04
—
0
12
0
23
0.00
0.59
0.0
1.5
—
—
—
0
0
34
403
0.76
0.59
2.9
3.6
65.94
81.75
ug/l
0.48
29
386
55
609
0.78
0.54
4.0
4.6
2.42
2.64
mmol/l
1.27
48
579
0
17
0.00
0.41
0.0
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
56
601
0.84
0.32
3.4
4.4
4.23
4.45
mmol/l
1.06
50
574
56
599
0.85
0.29
4.1
3.9
6.13
5.68
mmol/l
0.73
51
561
26
227
1.20
0.27
1.7
1.9
93.83
94.51
pmol/l
0.03
13
118
6
80
0.73
0.25
1.8
2.3
27.67
27.59
u/l
—
6
64
5
37
1.37
0.24
2.0
3.7
7.70
5.73
ug/l
—
5
23
57
602
0.87
0.22
3.8
4.0
14.92
14.69
pmol/l
0.24
51
567
0
11
0.00
0.21
0.0
5.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
1.16
—
0
11
0
10
0.00
0.21
0.0
1.2
—
0.75
—
0
10
0
10
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
51.87
—
0
13
18
156
1.19
0.20
4.5
3.9
8.10
10.75
mg/mmol
0.24
12
107
0
14
0.00
0.20
0.0
1.0
—
79.07
—
0
14
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
22
198
1.14
0.16
3.2
3.8
22.58
42.54
ng/l
0.97
17
133
11
126
0.86
0.12
3.7
3.9
19.10
21.03
%
—
5
49
34
332
1.04
0.02
1.3
1.8
0.36
2.68
u/ml
—
7
57
68
685
0.98
0.00
4.1
4.6
1.67
1.98
mu/l
2.26
62
648
48
485
0.98
0.00
3.0
4.3
54.26
41.78
u/l
0.56
42
469
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
97.83
—
0
6
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
74.00
—
0
5
0
5
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
3.41
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
2.37
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
7.02
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
0.83
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
7.20
—
0
5
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
63
0.95
-0.00
3.3
8.5
86.67
89.38
%
—
6
63
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
11.57
—
0
7
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
3.23
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
2.10
—
0
6
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
1.28
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
1.56
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
7.67
—
0
6
0
6
0.00
-0.00
0.0
3.8
—
0.67
—
0
6
0
5
0.00
-0.00
0.0
3.2
—
442.20
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint F5_SEVRET and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_SEVRET | 7.236 [4.69, 11.16] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.367 |
During the follow-up period (1.1.1998 — 31.12.2019), 263 out of 981 females with F5_SEVRET died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_SEVRET | 5.907 [4.34, 8.03] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.091 |
During the follow-up period (1.1.1998 — 31.12.2019), 324 out of 1391 males with F5_SEVRET died.
Mortality risk
Mortality risk for people of age
years, who have F5_SEVRET.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.712% | 1.176% |
| 5 | 4.535% | 7.074% |
| 10 | 9.503% | 17.82% |
| 15 | 18.507% | 31.6% |
| 20 | 31.77% | 46.652% |
Relationships between endpoints
↥Index endpoint: F5_SEVRET – Severe mental retardation
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data